NKGen Biotech, Inc.’s Post

🧩 The Alzheimer's puzzle: Why do treatments keep failing? The search for an effective Alzheimer's treatment has been ongoing for decades, yet a solution remains elusive. In a recent exploration of the setbacks, I discovered the complex challenges behind the disease's intricate biology and high clinical trial failure rates. With recent controversies like Biogen's Aducanumab approval, the landscape has become even more complicated. Despite this, there is hope with new approaches such as earlier intervention, combination therapies, and advanced diagnostics. What are your thoughts on the current state of Alzheimer's research? #Alzheimers #Pharma #Research

September is World Alzheimer's Month, a time to reflect on the impact of this devastating disease and reaffirm our commitment to advancing research. This month, we stand united with the global community in the fight against Alzheimer's. Our AQBioSim team brings AI to the forefront of drug discovery, rapidly simulating and optimizing billions of potential compounds to provide a comprehensive toolkit for drug development. Learn more about how AQBioSim is accelerating the discovery of new treatments: https://bit.ly/3MudG47 #AlzheimersAwareness #AQBioSim #Alzheimers #WorldAlzheimersMonth

Aduhelm (aducanumab) is set to be discontinued towards the end of the year, following its approval a few years ago. Active patients participating in #clinicaltrials will continue to have access until May, and prescriptions will be available until November. This shift marks Biogen's decision to refocus its efforts on Leqembi (Lecanemab-irmb), developed in collaboration with Eisai. With this renewed focus on Alzheimer's treatment, the aim is to broaden research initiatives targeting the multifaceted aspects of the disease and address unmet patient needs comprehensively. As the successor to Aducanumab, Leqembi signals a new chapter in #alzheimers therapy, promising further advancements and ongoing research. #ActivesPurpleTuesday #EndALZ 💜

Later on in the day, we had a conversation with Howard Fillit, MD, the cofounder and chief science officer of the Alzheimer's Drug Discovery Foundation, about the impact of combination therapies in the landscape of #Alzheimers disease treatment at #CTAD24! CTAD Clinical Trials on Alzheimer's Disease 🧠💊

Annovis receives green light to proceed with Phase 3 Pivotal Alzheimer's studies.   At the October 10 FDA meeting, Annovis was cleared to conduct two pivotal studies of buntanetap in early Alzheimer's patients, leading to two NDAs: one for symptomatic and one for disease-modifying efficacy. The first study is set to begin in Q1 2025, with a potential NDA filing within a year.   Find more details in the release: https://lnkd.in/ejMvaW2y   #Dementia #ClinicalTrials #NDAFiling #ClinicalTrials #Biotech #AlzheimersDisease #Alzheimer #PivotalStudies

Could human iPSCs help us to tackle the 99.6% failure rate for Alzheimer's Disease drug discovery? In this excerpt from our webinar "Tackling the Alzheimer's 99.6% problem", our Product Manager Dr Jan Turner explains the challenges for Alzheimer's Disease (AD) drug discovery. Our vision is to develop an AD "clinical trial in a dish" model comprising a large, diverse collection of patient samples to increase statistical power and enable patient stratification. To hear more about this, access the full webinar recording here: https://hubs.la/Q02xxm6Q0 #iPSCs #AlzheimersDisease #ClinicalTrialInADish #PatientStratification #StemCells

"It's a big feast of #biomarkers." - Howard Fillit, MD speaks to the most promising science being presented at CTAD Clinical Trials on Alzheimer's Disease, beginning with new advances in #bloodtests that are revolutionizing the clinical care and research landscapes. Many of these promising blood tests are led by companies funded through the ADDF's #DiagnosticsAccelerator, including C2N Diagnostics, ALZpath Inc. and Fujirebio.

Could human iPSCs help us to tackle the 99.6% failure rate for Alzheimer's Disease drug discovery? In this excerpt from our webinar "Tackling the Alzheimer's 99.6% problem", our Product Manager Dr Jan Turner explains the challenges for Alzheimer's Disease (AD) drug discovery. Our vision is to develop an AD "clinical trial in a dish" model comprising a large, diverse collection of patient samples to increase statistical power and enable patient stratification. To hear more about this, access the full webinar recording here: https://hubs.la/Q02xxm9F0 #iPSCs #AlzheimersDisease #ClinicalTrialInADish #PatientStratification #StemCells

Diagnostics is one area that has seen major advances in #Alzheimer's R&D. Only 10 years ago, #Alzheimers diagnosis relied on clinical observations. On the horizon are blood-based biomarker tests which can supplement the current standard of PET scans and lumbar punctures in the diagnosis of Alzheimer's. This article covers some of the rapid changes that are shaping the future of the Alzheimer's R&D landscape. https://ow.ly/Lrku50TeMT4 $INM #WorldAlzheimersMonth #Alzheimers #Research

Taking a personalized approach towards autoimmune cell therapy is vital for better outcomes. Ensure that the treatment aligns with the specific needs of the individual, considering factors like disease severity and responsiveness to prior medications. Stay informed about the latest advancements in cell therapies and consult with healthcare professionals to make well-informed decisions for managing autoimmune conditions. #AutoimmuneHealth #PersonalizedTherapy #CellTherapies #LupusTreatment #HealthcareInnovation BioMedHack.com is your leading source for the latest news, breakthroughs, and insights in medicine, biohacking, and alternative medicine. Our mission is to help you live healthier and longer by bringing you cutting-edge information and expert advice. Follow us on Facebook, Instagram, and X. Read more about this post here: https://lnkd.in/euGTizeM